About Us

Adeira Pharma has developed a first-in-class lipid nanoparticle drug formulation technology platform that offers a promising new path to formulating and targeting small molecule, peptide and protein-based therapeutics.

The nanoparticles range from 80 to 130 nanometers in diameter, can be targeted using standard antibody methods, and are composed entirely of excipients that have long and proven histories of safety and tolerability in parenteral uses. Studies in mouse and rat models show consistently higher maximum tolerated doses (MTD), as compared to conventional formulations. Early pharmacokinetic studies suggest a much higher circulation half-life and area under the curve (AUC).

These targeted nanoparticles are easily manufactured under GMP conditions using existing equipment and available USP-grade reagents, and can be stored for extensive periods of time without appreciable degradation. They may be terminally sterilized or sterile filtered.